NanoCellect Biomedical

company

About

NanoCellect Biomedical is a biotech company developing and commercializing cell analysis and sorting.

  • 11 - 50

Details

Last Funding Type
Series B
Last Funding Money Raised
$10M
Industries
Biotechnology,Health Care,Health Diagnostics,Medical Device
Founded date
Jan 1, 2009
Number Of Employee
11 - 50
Operating Status
Active

NanoCellect Biomedical, Inc. aims to make flow cytometry and cell sorting technology more affordable and accessible for life science researchers to perform cellular analysis, develop molecular diagnostics, and improve personalized medicine.

A critical element for biomedical research is the ability for scientists to analyze and isolate cells using flow cytometers. Scientists use flow cytometers to obtain a fast, objective and quantitative recording of fluorescent signals from individual cells as well as physical separation of cells of particular interest.

NanoCellect's mission is to facilitate breakthrough biomedical discoveries by making cell analysis and sorting technology more portable, affordable, and easier to use. We use microfluidics to make flow cytometers that enable biomedical scientists to analyze and sort cells required for drug discovery, diagnostics, or basic research.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
4
$45.25M
NanoCellect Biomedical has raised a total of $45.25M in funding over 2 rounds. Their latest funding was raised on Aug 13, 2021 from a Series D round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 13, 2021 Series D $20M 1 Detail
Feb 1, 2021 Series C $15M 1 Detail
Jan 12, 2018 Series Unknown $250K 2 Detail
Nov 29, 2017 Series B $10M 1 Detail

Investors

Number of Lead Investors
Number of Investors
4
NanoCellect Biomedical is funded by 4 investors. Sagian Equity and Highlander Venture Fund are the most recent investors.
Investor Name Lead Investor Funding Round
Sagian Equity Series D
Highlander Venture Fund Series Unknown
Triton Technology Fund Series Unknown
Agilent Technologies Series B